3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Endometrial Neoplasms
2
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
padeliporfin
2
talazoparib
1
sipuleucel-T
1
luprolide acetate gel depot
1
ixabepilone
1
enzalutamide
1
Therapeutics
1
Pluvicto
1
Paclitaxel
1
Nivolumab
1
Leuprolide
1
Ipilimumab
1
Imatinib Mesylate
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Diseases
×
talazoparib
×
Clear all
NCT06582628
2024-12-02
TEAM PC
Fundacion Oncosur
Phase 2
Recruiting
78 enrolled